Ripretinib
INSIGHT
Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 54
| Arm | Reported safety |
|---|---|
| Ripretinib 150 mg | n/r |
| Sunitinib 50 mg 4/2 | n/r |
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Ripretinib
Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 54
| Arm | Reported safety |
|---|---|
| Ripretinib 150 mg | n/r |
| Sunitinib 50 mg 4/2 | n/r |
A count stays a count. This page does not turn a count into a percent.